ClinicalTrials.gg
RecruitingNCT01893710Updated Apr 30, 2026

International (Pediatric) Peritoneal Biobank

An observational study in Kidney Failure, Chronic, Peritoneal Dialysis Complication and Transplantation, sponsored by Heidelberg University. Recruiting at 26 sites in 15 countries. Open to participants aged 1 Day to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Heidelberg University · Observational

How we know

From the registry’s dates

  • Started Feb 2011; still recruiting 15 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
500
Ages
1 Day to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 109 studies in Kidney Failure, Chronic with a site in Germany — 9 open to participants now, 15 under way, 4 of them phase 3. Kidney Failure, Chronic · Germany.

Planned enrollment
8th of 23
500 · median 119
Started
2011
with 4 others
Observational
23 of 109
4 open now
Primary completion
2028-10
later than 8 of 14 live
Registered
51st of 109
by date
Lead sponsor
5 of 109
Heidelberg University

Among the 109 studies in Kidney Failure, Chronic with a site in Germany, this one is the 8th largest by planned enrollment of the 23 observational ones that give a count, is one of 5 that started in 2011, is one of 23 observational ones, reaches primary completion later than 8 of the 14 other live ones, and was the 51st registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

9 of the 109 studies in Kidney Failure, Chronic with a site in Germany are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 1 Day to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Kidney Failure, Chronic with a site in Germany, or all of them as a file.
02

Study summary

Within few years the peritoneal membrane of adult peritoneal dialysis (PD) patients undergoes substantial morphological transformation, including progressive fibrosis, vasculopathy and neoangiogenesis. Ultrafiltration capacity steadily declines and ultimately results in PD failure. In children, peritoneal biopsies demonstrating PD associated alterations have not yet been obtained. They, however, should be particularly informative, since secondary tissue and vascular pathology related to ageing or diabetes is absent.

An international, prospective peritoneal membrane biopsy study in children on PD will therefore be performed. Biopsies will be obtained at time of PD catheter insertion, on occasion of intercurrent abdominal surgery (e.g. hernia repair, catheter exchange) and at time of renal transplantation. Quantitative histomorphometry and tissue protein expression analyses will be correlated with time integrated PD treatment modalities and functional characteristics as well as inflammatory and cardiovascular comorbidity surrogate parameter. Blood will be obtained during clinical routine sampling. Biopsies will be obtained during clinically indicated operations, without substantially increasing operation time and associated surgical risks. The detailed histomorphometry of the PD membrane will give additional information, potentially impacting on the individual PD regime.

3/2018: The analyses of the pediatric PD biopsy demonstrated early and major transformation of the peritoneal membrane with neutral pH low GDP fluids, and significant vasculopathy already in children with CKD stage 5, further progressing with PD. The underlying mechanisms are partly understood, only. In view of these major findings and the numerous open questions, collection of biosamples will be continued in children and also in adult PD patients. The following questions will be addressed: Molecular counterparts of peritoneal semi-permeability, solute and water transport (beyond AQP1), pathomechanisms and molecular and functional impact of peritoneal transformation with low and high GDP fluids, and the respective pathomechanisms and molecular and functional impact of vascular disease in CKD and with different PD fluids. The impact of renal transplantation following PD will be assessed in a subgroup of patients with tenckhoff catheter removal several weeks after transplantation and a functioning graft.

Read the detailed description

Please see study protocol and

http://www.pedpd.org

03

Conditions studied

  • Kidney Failure, Chronic
  • Peritoneal Dialysis Complication
  • Transplantation
  • Healthy

Keywords

  • peritoneal dialysis
  • parietal peritoneum
  • omentum
  • chronic kidney disease
  • vasculopathy
04

Who can participate

Ages eligible
1 Day to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

See eligibility data

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 0 to 90 years
  • CKD 5D, peritoneal dialysis and
  • Patients with normal renal function and elective abdominal surgery due to limited abdominal pathology (such as hernia repair, gallstones….)
  • Patients post PD and post Tx
  • Oral and written consent
  • Ability to consent of the adult patient and of the parents and legal guardian of patients not yet of legal age, respectively

Exclusion criteria

Exclusion Criteria:

  • Abdominal adhesions, malformation and inflammation beyond PD induced changes
  • Patients with disseminated tumour disease
  • Patients with critical heart failure and other medical conditions, where the additional procedure may confer an increased increase risk
  • Pregnancy
  • Preterm babies (below 37 weeks of gestational age)
  • Serum \< 10 g/dl in newborns and \< 8 g/dl in children and adults
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Control

    'Biopsy sampling': Peritoneal biopsies without kidney disease, i.e. diseases not related to the kidney and not affecting the peritoneum. This group is accomplished.

  • chronic kidney disease

    Samples will obtained from patients with chronic kidney disease stage 5 (at time of catheter Insertion)

    Procedure: biopsy sampling

  • Peritoneal dialysis

    Patients on PD with different PD fluids and intercurrent abdominal surgery and at time of renal transplantation.

    Procedure: biopsy sampling

  • Post PD and with functioning graft

    Samples will also be collected and analysed from patients with renal transplantation after PD at time of and tenckhoff catheter removal several weeks after Tx or other intercurrent abdominal surgery.

    Procedure: biopsy sampling

Interventions

  • Procedurebiopsy sampling

    Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained. Biopsy sampling will be performed in all groups. This is an observational not an interventional trial.

06

What researchers measure

Primary outcomes

  1. Peritoneal vasculopathy (lumen vessel ratio)

    Digital quantification of degree of vasculopathy, i.e the lumen vessel ratio. Healthy children have a L/V ratio of about 0.7. lower values represent vasculopathy with lumen narrowing, 0 is complete obliteration of the vessel. This measurements will be accompanied by molecular analysis of pathomechanisms (including omics Technology)

    Time frame: Two years (Mean PD treatment time)

Secondary outcomes

  1. Number of vessels per peritoneal membrane area (per mm²)

    Digital histomorphometry of small vessel density per mm² submesothelial section area analysed.

    Time frame: at time of catheter insertion, intercurrent abdominal surgery and at time of renal transplantation

Other outcomes

  1. Submesothelial thickness (µm)

    Digital imaging analysis of submesothelial thickness as a marker of peritoneal fibrosis (distance between mesothelium and adjacent muscle/adipos tissue)

    Time frame: 2 years (average PD duration)

  2. Submesothelial lymphocyte, macrophage, MMT cell count

    Quantification of peritoneal leucocyte Infiltration, i.e. number of CD45 positive lymphocytes and CD68 positive macrophages per mm² of submesothelial section area . The number of cells that underwent mesothelial-mesenchymal transition per mm² submesothelial section are quantified by immunohistochemical co-staining of mesothelial and fibroblast marker (cytokeratin and FSP1).

    Time frame: 2 years (mean PD duration)

  3. Peritoneal VEGF and pSMAD abundance

    Key cytokines involved in peritoneal membrane transformation will be measured immunohistochemically. These are VEGF and TGF-beta induced p-SMAD (%positive area per section area analysed).

    Time frame: 2 years (mean PD duration)

07

Study locations

17 of 26 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
    Recruiting
    • Bradley A. Warady, MD · Contactbwarady@cmh.edu · +1 8162343010
    • Bradley A. Warady, MD · Principal investigator
  • The Children´s Hospital of Philadelphia
    Narberth, Pennsylvania 19104, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Department of Pediatrics, Medical University Vienna
    Vienna, 1090, Austria
    Recruiting
  • UZ Ghent
    Ghent, 9890, Belgium
    Recruiting
  • University Children's Hospital
    Prague, 15006, Czechia
    Recruiting
    • Karel Vondrak, MD · Contact8080@seznam.cz · +42 0224432078
    • Karel Vondrak, MD · Principal investigator
  • Service de Néphrologie Pédiatrique, Hôpital Femme Mere Enfant
    Lyon, 69677, France
    Recruiting
  • University Children's Hospital
    Strasbourg, 67098, France
    Recruiting
  • Department of Medicine I (Nephrology), University of Heidelberg
    Heidelberg, Baden-Wurttemberg 69120, Germany
    Recruiting
  • University Children's Hospital
    Berlin, 10117, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Children's Hospital
    Cologne, 50931, Germany
    Recruiting
  • University Children's Hospital
    Essen, 45122, Germany
    Recruiting
  • UKE, University Children´s Hospital
    Hamburg, 20251, Germany
    Recruiting
    • Jun Oh, MD · Contactj.oh@uke.de · +49 40 7410 0
    • Christian Brix, MD · Sub investigator
  • KfH Pediatric Kidney Center, Department of Pediatric Nephrology, University of Marburg
    Marburg, 35043, Germany
    Recruiting
  • University Children's Hospital
    Budapest, 1083, Hungary
    Recruiting
  • University Children'Hospital
    Genova, 16147, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Children's Hospital
    Milan, 20122, Italy
    Recruiting
    • Sara Testa, MD · Contactsaratesta@tiscali.it · +39 0257992471
    • Sara Testa, MD · Principal investigator
  • Pediatric Nephrology, Dialysis and Transplant Unit
    Padova, 35128, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University children's Hospital
    Vilnius, 08406, Lithuania
    Recruiting
    • Rimante Cerkauskiene, MD · Contactrimantec@yahoo.com · +37 052720427
    • Rimante Cerkauskiene, MD · Principal investigator
  • Paediatric CAPD unit, Kuala Lumpur Hospital
    Kuala Lumpur, 50586, Malaysia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Krakow, Jagiellonian University Medical College
    Krakow, 30663, Poland
    Recruiting
  • Hospital Universitario Materno-Infantil Vall d' Hebron
    Barcelona, 08035, Spain
    Recruiting
    • Gema Ariceta, MD · Contactgariceta@vhebron.net · +34 934893082
    • Gema Ariceta, MD · Principal investigator
  • Karolinska University Hospital
    Stockholm, 17176, Sweden
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Children's Hospital, Inselspital, Bern University Hospital and University of Bern
    Bern, 3010, Switzerland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Children's Hospital
    Adana, 01330, Turkey (Türkiye)
    Recruiting
    • Aysun K Bayazit, MD · Contactayskar@cu.edu.tr · +90 3223386935
    • Aysun K Bayazit, MD · Principal investigator
  • Cerrahpasa School of Medicine
    Istanbul, 34303, Turkey (Türkiye)
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Publications

  • Levai E, Marinovic I, Bartosova M, Zhang C, Schaefer B, Jenei H, Du Z, Drozdz D, Klaus G, Arbeiter K, Romero P, Schwenger V, Schwab C, Szabo AJ, Zarogiannis SG, Schmitt CP. Human peritoneal tight junction, transporter and channel expression in health and kidney failure, and associated solute transport. Sci Rep. 2023 Oct 13;13(1):17429. doi: 10.1038/s41598-023-44466-z. PubMed 37833387 ↗
  • Catar RA, Bartosova M, Kawka E, Chen L, Marinovic I, Zhang C, Zhao H, Wu D, Zickler D, Stadnik H, Karczewski M, Kamhieh-Milz J, Jorres A, Moll G, Schmitt CP, Witowski J. Angiogenic Role of Mesothelium-Derived Chemokine CXCL1 During Unfavorable Peritoneal Tissue Remodeling in Patients Receiving Peritoneal Dialysis as Renal Replacement Therapy. Front Immunol. 2022 Feb 4;13:821681. doi: 10.3389/fimmu.2022.821681. eCollection 2022. PubMed 35185912 ↗
  • Bartosova M, Zhang C, Schaefer B, Herzog R, Ridinger D, Damgov I, Levai E, Marinovic I, Eckert C, Romero P, Sallay P, Ujszaszi A, Unterwurzacher M, Wagner A, Hildenbrand G, Warady BA, Schaefer F, Zarogiannis SG, Kratochwill K, Schmitt CP. Glucose Derivative Induced Vasculopathy in Children on Chronic Peritoneal Dialysis. Circ Res. 2021 Aug 20;129(5):e102-e118. doi: 10.1161/CIRCRESAHA.121.319310. Epub 2021 Jul 8. PubMed 34233458 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2011 (actual). Primary completion is estimated for Oct 2028, 212 months after the start.

Of 132 non-industry observational studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 62. This study's planned 212 months is above that.

Counting every sponsor, half of 151 studies reached it within 29 months; a quarter within 11 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2013
First posted
Jul 9, 2013
StartActual
Feb 1, 2011
Primary completionEst.
Oct 1, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01893710
Responsible party
Claus Peter Schmitt (MD, Heidelberg University) — Principal investigator
First posted
Jul 9, 2013
Start date
Feb 1, 2011
Primary completion
Oct 1, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 30, 2026

Study contacts

Claus P Schmitt, Prof
Contact
claus.peter.schmitt@med.uni-heidelberg.de
+49 6221 56 ext. 39313
Claus P Schmitt, MD
principal investigator · University of Heidelberg, Center for Pediatric and Adolescent Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion